U.S. Launch Prices for New Drugs Fell in 2025 as Fewer Costly Gene Therapies Reached Market
核心洞察
Median annual list price for newly approved drugs dropped to $216,000 in 2025 from over $370,000 in 2024, driven by a decline in approved cell and gene therapies.
The FDA approved 51 new drugs in 2025, with more than 67% being small-molecule drugs, up from 62% in 2024, shifting the pricing mix downward.
Experts caution the decline reflects the composition of approvals rather than fundamental pricing reform, with political pressure from the Trump administration described as largely "performative."
Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, yet remained high at a median of $216,000 due to expensive drugs for rare diseases, according to a new analysis by 3 Axis Advisors.
In 2024, the median annual list price of a new drug was over $370,000, up from $300,000 in 2023 and $222,000 in 2022. The average launch price for a drug approved in 2025 was $416,000, as lower-cost products offset expensive treatments for rare genetic disorders.
Drug pricing experts attributed the dip to the mix of types of drugs approved rather than a significant shift in pricing strategy or government policies aimed at lowering prescription drug prices. The Food and Drug Administration (搜索) last year approved five cell and gene therapies versus seven in both 2024 and 2023. Gene therapies, which are given once, can have prices in the millions of dollars.
"It is hard to make a lot of assessments about trends based on a single year," said Dr. Benjamin Rome, an assistant professor at Harvard Medical School who researches drug prices, adding that "2025 was an odd year."
Small Molecules Dominate Approvals
More than 67% of FDA approvals in 2025 were for small-molecule drugs, such as pills, which are made from chemicals, rather than costly, complex biologics derived from living cells. That number was up from 2024, when small molecules accounted for 62% of approvals, and 2023, when it was 57%.
New biologics are often first-in-class and do not have competitors, allowing drugmakers to charge high prices, said Richard Frank, director at the Brookings Institution's Center on Health Policy.
The analysis of 42 drug prices compiled by 3 Axis Advisors excluded drugs used intermittently like antibiotics and products that have not yet launched commercially. Lower-cost products included LENZ Therapeutics (搜索)' Vizz (搜索) eye drops for blurry vision at $1,050 and LIB Therapeutics (搜索)' cholesterol drug Lerochol (搜索) at $5,400, while Mighty Therapeutics (搜索)' Forzinity (搜索) for Barth syndrome (搜索) was priced at nearly $800,000 a year.
Political Pressure and Regulatory Turbulence
Rome noted that the FDA was buffeted by Trump administration reorganization efforts, including staff cuts and leadership changes. The agency rejected several gene therapies, leading to a backlash from patient advocates and political controversy. Earlier this year, the FDA said it would take a more flexible approach.
Drugmakers came under pressure from President Donald Trump, who has sought to claim victory in tackling high U.S. pharmaceutical prices with the TrumpRx platform for direct-to-consumer sales, and deals with large companies to bring U.S. prices in line with those in other developed nations.
Those agreements are unlikely to last beyond the current administration, said Brookings' Frank. Rome also said that without legislation, the agreements will not significantly impact pricing decisions.
"There's been this broad trend to say look what I'm doing to lower drug prices," but a lot of it is "performative," said Geoffrey Joyce, director at the University of Southern California's Schaeffer Center for Health Policy & Economics.
Cancer and Rare Disease Focus
The FDA approved 51 new drugs last year, 46 at its main division and the five cell and gene therapies. The agency approved 57 new drugs in 2024 and 55 in 2023. Those tallies do not include imaging agents, blood testing reagents or vaccines.
Cancer drugs remained the most represented therapeutic area, accounting for about a third of 2025 FDA approvals. As in recent years, more than half of the approvals were "orphan" drugs, meaning they treat conditions affecting fewer than 200,000 Americans. Drugmakers are given incentives to invest in research for rare diseases, including longer market exclusivity, and often charge premium prices for the niche products.
While calling that "wise public policy," USC's Joyce noted that drugmakers have "gamed" those incentives. They can develop a drug that is effective for a wide range of conditions but seek approval for "a low-prevalence disease… and get all the benefits and all the tax write-offs," he said. "The logic is to launch (at a price) as high as you think you can get away with."
Limitations and Outlook
Many new medicines target serious, complex diseases with few or no treatment options, and it is "misleading" to compare those prices to other drug types, trade group Pharmaceutical Research and Manufacturers of America (搜索) said in an email.
The analysis looked only at list prices and did not include the undisclosed discounts and rebates that insurers can receive from manufacturers. Drug companies emphasize that new medicines can offer cost-saving value, including potentially fewer emergency room visits and hospital stays.
"You're still paying hundreds of thousands of dollars for most new drugs… irrespective of whether they offer a huge benefit over existing drugs or are sort of novel products that don't offer much benefit," Harvard's Rome said.